Skip to content

Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging

Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging (CARDIO IRM)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05877755
Acronym
CARDIO-IRM
Enrollment
200
Registered
2023-05-26
Start date
2025-04-15
Completion date
2030-03-31
Last updated
2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease

Keywords

Cardiac MRI, Sequences, High-resolution, Multi-contrast, Imaging

Brief summary

Cardiovascular disease (CVD) causes at least 1.8 million European deaths annually, exceeding fatalities from cancer, chronic respiratory disease, and diabetes. Consequently, the fight against CVD has become the main priority of the World Health Organization. In the pursuit of understanding and treating CVD, cardiac magnetic resonance imaging (CMR) has remained the only modality capable of providing a comprehensive assessment of the heart's function and structure without harmful radiation. Unfortunately, current CMR systems remain too slow, too complex, require highly trained specialists and, as such, have presented a barrier to a wider adoption of CMR. The aim of CARDIO-IRM is to unleash the full potential of CMR to transform patient trajectories by introducing a fast, one-click, fully automated, and comprehensive imaging pipeline applicable to diagnosis, prognosis, and therapy selection in cardiology.

Detailed description

Cardiovascular disease (CVD) causes at least 1.8 million European deaths annually, exceeding fatalities from cancer, chronic respiratory disease, and diabetes. Consequently, the fight against CVD has become the main priority of the World Health Organization. In the pursuit of understanding and treating CVD, cardiac magnetic resonance imaging (CMR) has remained the only modality capable of providing a comprehensive assessment of the heart's function and structure without harmful radiation. Unfortunately, current CMR systems remain too slow, too complex, require highly trained specialists and, as such, have presented a barrier to a wider adoption of CMR. The aim of this project is to unleash the full potential of CMR to transform patient trajectories by introducing a fast, one-click, fully automated, and comprehensive imaging pipeline applicable to diagnosis, prognosis, and therapy selection in cardiology. This aim will be achieved by (i) creating a novel imaging technology that collects CMR data in a single continuous free-breathing scan, taking into account post-processing requirements at the very origin of CMR sequence design; (ii) exploiting the unique contrasts generated by this technology to automatically extract quantitative markers on cardiac anatomy, function, and tissue characteristics; and (iii) translating this transformative technology to a clinical setting. This will be the first-ever integrated cardiac imaging pipeline in which CMR images are acquired in a single click, jointly represented in a single volume, and automatically analysed. This will unlock obstacles for broader acceptance of CMR and unleash the full potential of CMR to maximize its impact on patient trajectories. The results of this project will pave the way towards robust image-based strategies for personalized patient care (diagnosis, risk stratification, therapy selection, monitoring, and image-guided interventions).

Interventions

DEVICECardiac MRI acquisition

All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.

Sponsors

Grant Agreement ERC SMHEART
CollaboratorUNKNOWN
University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patient (over 18 years of age) requiring an MRI scan as part of their care. * Male or female. * Affiliated or beneficiary of a social security scheme * Having given his/her oral no objection after having read the information note

Exclusion criteria

* Patient unable to give oral consent (guardianship, non-French speaker, etc.) * Patient deprived of liberty * Patient who does not meet the specific eligibility criteria for an MRI examination: pregnant women, known pathology that may interfere with acquisition (e.g. Parkinson's disease), absolute or relative contraindication to an MRI examination * Patient participating in a therapeutic interventional trial or in a period of relative exclusion in relation to another protocol

Design outcomes

Primary

MeasureTime frameDescription
Imaging integration success60 monthsMeasure of image quality according to signal-to-noise ratio

Secondary

MeasureTime frameDescription
Integration of the collected images in an internal database to develop new reconstruction and image processing algorithms specific to this application (e.g. using artificial intelligence)60 monthsMeasure of training time and training loss function
Cardiac MRI feature: location and size of myocardial scars/fibrosis60 monthsMeasured in mL on late gadolinium enhancement images
Cardiac MRI feature native parameter values (T1, T2, T1-rho, T2*)60 monthsMeasured in milliseconds
CMR feature extracellular volume fraction (ECV)60 monthsMeasured in mL/m2
CMR feature ejection fraction60 monthsMeasured in percentage

Countries

France

Contacts

Primary ContactBUSTIN Aurelien, PHD
aurelien.bustin@ihu-liryc.fr+33 6 16 29 05 91
Backup ContactCOCHET Hubert, MD, PHD
hubert.cochet@chu-bordeaux.fr+33 5 57 65 65 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026